Skip to main content

Table 4 PROMs scores and change by LTC

From: Change in health status in long-term conditions over a one year period: a cohort survey using patient-reported outcome measures

N

Baseline mean

Follow-up mean

Mean change

Lower CI (95%)

Upper CI (95%)

p

Asthma EQ-5D

York A1 tariff

255

0.83

0.84

0.01

0.00

0.02

0.23

VAS

248

73.77

74.33

0.56

−1.09

2.21

0.50

Asthma MINI-AQLQ

Symptoms

252

5.29

5.29

0.00

−0.12

0.12

0.99

Activity Limitations

240

6.08

5.92

−0.15

−0.26

−0.05

0.00

Emotional Functioning

253

5.37

5.28

−0.09

−0.23

0.05

0.21

Environmental Stimuli

255

5.30

5.24

−0.05

−0.17

0.07

0.38

Total QOL

226

5.60

5.52

−0.07

−0.17

0.02

0.13

N

Baseline mean

Follow-up mean

Mean change

Lower CI (95%)

Upper CI (95%)

p

COPD EQ-5D

York A1 tariff

177

0.67

0.67

0.00

−0.02

0.01

0.77

VAS

173

62.29

62.14

−0.14

−2.94

2.66

0.92

COPD CCQ

Symptoms

171

2.60

2.60

0.01

−0.14

0.16

0.92

Functional State

176

2.03

2.14

0.11

−0.03

0.25

0.12

Mental State

174

2.11

2.20

0.10

−0.09

0.29

0.32

Total QOL

160

2.22

2.28

0.06

−0.07

0.19

0.38

N

Baseline mean

Follow-up mean

Mean change

Lower CI (95%)

Upper CI (95%)

p

Diabetes EQ-5D

York A1 tariff

301

0.73

0.72

0.00

−0.01

0.01

0.60

VAS

296

68.16

69.76

1.60

−0.19

3.39

0.08

Diabetes DHP

Psychological distress

301

16.35

16.59

0.24

−1.09

1.57

0.72

Barriers to activity

282

22.17

22.39

0.22

−1.22

1.66

0.76

Disinhibited eating

307

30.16

30.08

−0.09

−1.71

1.54

0.92

N

Baseline mean

Follow-up mean

Mean change

Lower CI (95%)

Upper CI (95%)

p

Epilepsy EQ-5D

York A1 tariff

95

0.76

0.76

0.00

−0.02

0.02

0.89

VAS

91

71.40

73.59

2.20

−0.96

5.36

0.17

Epilepsy QOLIE

Seizure worry

95

64.49

65.32

0.82

−3.05

4.69

0.67

Overall QOL

79

68.26

68.58

0.32

−2.79

3.42

0.84

Emotional well-being

95

67.58

67.24

−0.34

−3.69

3.02

0.84

Energy

98

54.34

51.99

−2.35

−5.18

0.49

0.10

Cognitive

89

63.92

64.69

0.77

−2.18

3.73

0.60

Medication effects

98

62.59

61.65

−0.94

−5.67

3.80

0.70

Social function

53

79.25

79.04

−0.21

−5.14

4.73

0.93

Total QOL

40

69.92

70.13

0.22

−2.93

3.36

0.89

N

Baseline mean

Follow-up mean

Mean change

Lower CI (95%)

Upper CI (95%)

p

Heart failure EQ-5D

York A1 tariff

137

0.64

0.64

0.00

−0.02

0.01

0.62

VAS

145

62.20

58.67

−3.53

−6.69

−0.38

0.03

Heart failure MLHFQ

Total QOL

80

36.91

35.10

−1.81

−4.46

0.84

0.18

Physical dimension

125

18.44

18.02

−0.42

−1.62

0.77

0.48

Emotional dimension

132

7.79

7.48

−0.31

−0.99

0.36

0.36

N

Baseline mean

Follow-up mean

Mean change

Lower CI (95%)

Upper CI (95%)

p

Stroke EQ-5D

York A1 tariff

93

0.67

0.67

−0.01

−0.03

0.01

0.45

VAS

82

73.84

71.96

−1.88

−5.12

1.37

0.25

Stroke SIS

Strength

72

66.75

65.97

−0.78

−5.22

3.66

0.73

Hand function

76

73.22

72.17

−1.05

−3.67

1.57

0.43

Mobility

79

78.83

76.72

−2.11

−4.46

0.24

0.08

Memory

91

81.32

81.04

−0.27

−3.23

2.68

0.85

ADL

80

82.22

79.66

−2.56

−4.48

−0.65

0.01

Communication

92

86.88

85.05

−1.82

−4.26

0.61

0.14

Emotion

77

72.08

71.90

−0.18

−3.56

3.20

0.92

Handicap

48

72.20

72.92

0.72

−3.78

5.21

0.75

Physical dimension

52

78.08

76.35

−1.72

−3.67

0.23

0.08